Ionis Pharmaceuticals, Inc. (IONS) Discusses Detailed Phase III Results for Olezarsen in Severe Hypertriglyceridemia Transcript

Core Insights - The conference call is focused on discussing the detailed results of Phase III trials for olezarsen [1] Group 1 - The call is being led by Wade Walke, Senior Vice President of Investor Relations [1]